News Teva Pharmaceuticals Launches First Revlimid Generic March 8, 2022 Read More » Opdivo Granted Additional Lung Cancer Indication March 4, 2022 Read More » Aspruzyo Sprinkle Approved for Chest Pain March 3, 2022 Read More » Carvykti Approved for Multiple Myeloma March 1, 2022 Read More » Releuko, a New Biosimilar for Neupogen, Receives FDA Approval March 1, 2022 Read More » Brand Medications with Generic Alternatives Anticipated to be Approved in March March 1, 2022 Read More » Vonjo Granted Approval to Treat Rare Cancer February 28, 2022 Read More » Jardiance Receives New Heart Failure Indication February 24, 2022 Read More » First Restasis Generic Approved for Dry Eye February 2, 2022 Read More » Page1 … Page33 Page34 Page35 Page36 Page37 Benefit Advisors & Employees - Want to know more? Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager Full Name(Required)Email(Required) Comment(Required)Company Name(Required)CAPTCHA
Brand Medications with Generic Alternatives Anticipated to be Approved in March March 1, 2022 Read More »